People and Places

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 3
Volume 16
Issue 3

Dr. Richard Schilsky, Dr. Edward Pan, Pam Kedziera

Dr. Richard Schilsky

Richard L. Schilsky, MD, associate dean for clinical research at the University of Chicago Pritzker School of Medicine, has been elected president of the American Society of Clinical Oncology for the 2008-2009 term. He will be inducted as president-elect at ASCO's 43rd Annual Meeting in June 2007. Dr. Schilsky's interests include GI cancers, cancer pharmacology, and drug development.

Dr. Edward Pan

The Orlando campus of M.D. Anderson has added neuro-oncologist Edward Pan, MD, to its staff. Dr. Pan comes to M.D. Anderson from the Florida Hospital Cancer Institute where he was co-medical director of neuro-oncology. Prior to that appointment, he was on faculty as a clinical instructor for the Brain Tumor Research Center at the University of California, San Francisco.

Pam Kedziera

Fox Chase Cancer Center has named Pam Kedziera, RN, MSN, ACON, as clinical director of the center's pain and palliative care program. In her new role, she will help lead expansion of the pain management center into a broader focused program while continuing to direct the staff and programs offered at the center. Ms. Kedziera has been affiliated with Fox Chase since 1980.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content